Related Experiment Video
Updated: Aug 2, 2025
06:02
Production of siRNA-Loaded Lipid Nanoparticles using a Microfluidic Device
Published on: March 22, 2022
9.2K
Preparation and Characterization of IL-22 mRNA-loaded Lipid Nanoparticles
Zahra Alghoul1,2, Junsik Sung1, Kenji Wu1
1Institute for Biomedical Sciences, Digestive Diseases Research Group, Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA, USA.
Bio-Protocol
|April 14, 2023
Summary
Oral delivery of lipid nanoparticles carrying Interleukin-22 (IL-22) mRNA effectively treats colitis. This approach overcomes challenges of direct injection, offering a promising new method for colon-targeted nucleic acid delivery.
Area of Science:
- Biotechnology
- Immunology
- Gastroenterology
Background:
- Interleukin-22 (IL-22) is vital for epithelial repair and has anti-inflammatory properties relevant to ulcerative colitis.
- Current IL-22 cDNA vector delivery via microinjection faces technical hurdles for colon targeting.
- Oral administration presents a viable alternative for effective, targeted drug delivery.
Purpose of the Study:
- To detail the preparation and characterization of novel lipid nanoparticles (nLNP) encapsulating IL-22 mRNA.
- To establish an oral delivery system for IL-22 mRNA targeting the colon.
- To provide a versatile nLNP platform for colon-targeted nucleic acid delivery.
Main Methods:
- Preparation of nLNP using three key lipids, mimicking natural ginger-derived nanoparticles.
- Encapsulation of IL-22 mRNA within the synthesized nLNP.
- Characterization of the resulting nLNP-encapsulated IL-22 mRNA.
Main Results:
- Successful preparation and characterization of nLNP-encapsulated IL-22 mRNA.
- Demonstrated colon-targeting capability of the oral nLNP formulation.
- Effective amelioration of colitis in preclinical models.
Conclusions:
- Oral administration of nLNP-encapsulated IL-22 mRNA is an effective strategy for treating colitis.
- This nLNP platform offers a practical solution for colon-targeted nucleic acid delivery, overcoming microinjection limitations.
- The developed nLNP system holds potential for delivering various nucleic acids to the colon for therapeutic applications.
